Skip to main content
Michael Heffernan, MD, Dermatology, San Luis Obispo, CA

Michael P Heffernan MD

Dermatology•San Luis Obispo, CA

Dermatologist at San Luis Dermatology

Join to view full profile

  • 15 Santa Rosa StSan Luis Obispo, CA 93405

  • Phone+1 805-541-2650

  • Fax+1 805-541-4043

Dr. Heffernan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Heffernan's full profileAlready have an account?

Summary

  • Dr. Heffernan is an owner of San Luis Dermatology and the President of Heffernan Consulting LLC in San Luis Obispo, CA. As a researcher, Dr. Heffernan leads the US Dermatology operations for Probity Medical Research, a global consortium of clinical research sites. Dr. Heffernan has been the author of over 70 publications and textbook chapters. He has been an investigator on over 150 research protocols and he has given over 500 lectures around the globe.
    Prior to returning to the practice of Dermatology, Dr. Heffernan was a Distinguished Medical Fellow and Senior Medical Director for Eli Lilly & Co. Previously, he served as Chairman of the Department of Dermatology at the Wright State University Boonshoft School of Medicine. He has held faculty appointments at the Uniformed Services University of the Health Sciences, Washington University School of Medicine, and the Indiana University School of Medicine.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 1994 - 1997
  • University of Michigan
    University of MichiganInternship, Internal Medicine, 1993 - 1994
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1993
  • University of Notre Dame
    University of Notre DameBS, 1985 - 1989
  • University of Notre Dame
    University of Notre DameBS, Preprofessional Studies, 1985 - 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2028
  • FL State Medical License
    FL State Medical License 2012 - 2016
  • IN State Medical License
    IN State Medical License 2013 - 2015
  • MO State Medical License
    MO State Medical License 2009 - 2015
  • OH State Medical License
    OH State Medical License 1998 - 2010
  • MI State Medical License
    MI State Medical License 1993 - 1994
  • Dermatology
    American Board of Dermatology Dermatology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EMA Mobile, Modernizing Medicine, Inc., 2016-2017
  • CMS Meaningful Use Stage 1 Certification EMA, Modernizing Medicine, Inc., 2016-2017
  • Scholars Circle Dermatology Foundation, 2004

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naïve and TNF-IR Patients with Rheumatoid Arthritis  
    Genovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Heffernan MP, Carlier H, J Rheumatol., 1/15/2015
  • A high level of clinical response is associated with improved patient-reported outcomes in psoriasis:analyses from a phase 2 study in patients treated with ixekizumab  
    Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, et al., J Eur Acad Dermatol Venereol, 1/13/2015
  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials  
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickol..., Lancet, 1/8/2015

Books/Book Chapters

  • Fitzpatrick’s Dermatology in General Medicine 
    Chapter: CHAPTER 205 “Superficial Fungal Infections.” 
    Verma S, Heffernan MPEdition 7th,2007
  • Fitzpatrick Dermatology in General Medicine 
    Chapter: CHAPTER 145 "Skin Manifestations of Bone Marrow and Blood Disorders" 
    Heffernan MP, Houshmand E, Rashid BAEdition 7th,2007
  • Fitzpatrick Dermatology in General Medicine 
    Chapter: CHAPTER 206 "Yeast Infections: Candidiasis, Pityriasis (Tinea) Versicolor" 
    Janik MP, Heffernan MPEdition 7th,2007

Abstracts/Posters

  • Off-Label Uses of Biologics.
    Heffernan MP, Utah Dermatology Society, Springdale, UT, 1/13/2010
  • Practical Approaches to Patient Problems.
    Heffernan MP, AAD Annual Meeting, 1/1/2010
  • Preliminary results on AAD formal leadership training programs for early career dermatologists.
    Morrison LK, Malone M, Carr D, Heffernan M, Marks V, American Academy of Dermatology Annual Meeting, 1/1/2010

Lectures

  • Biologics 2015 and Beyond. 
    18th Annual Winter Clinical Dermatology Meeting - 1/1/2015
  • What the Sponsor Expects. 
    Coastal Dermatology Meeting - 1/1/2015
  • Biologics Beyond Psoriasis. 
    Coastal Dermatology Meeting - 1/1/2015

Other

  • Persistant Cutaneous Hyperpigmentation due to Hydroxychloroquinone One Year After Therapy Discontinuation. 
    Morrison LK, Nordlund JJ, Heffernan MP, Dermatology Online Journal
    1/1/2009
  • Treatment Options for Atopic Dermatitis – 2007 Update. 
    Heffernan MP, Houshmand E, US Special Populations: Pediatrics Review
    1/1/2006
  • Mycology #1. 
    Anadkat MJ, Kanzler MH, Gorsulowsky DC, Heffernan MP, National Library of Dermatologic Teaching Slides #50
    1/1/2004

External Links

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Michael Heffernan, Dr. Michael Heffernan, MD, Dr. M Heffernan, Dr. Michael P Heffernan